Display options
Cite
Iwasaki S, Akisawa N, Saibara T, et al. Fibrate for treatment of primary biliary cirrhosis. Hepatol Res. 2007;37:S515-7doi: 10.1111/j.1872-034X.2007.00232.x.
Iwasaki, S., Akisawa, N., Saibara, T., & Onishi, S. (2007). Fibrate for treatment of primary biliary cirrhosis. Hepatology research : the official journal of the Japan Society of Hepatology, 37S515-7. https://doi.org/10.1111/j.1872-034X.2007.00232.x
Iwasaki, Shinji, et al. "Fibrate for treatment of primary biliary cirrhosis." Hepatology research : the official journal of the Japan Society of Hepatology vol. 37 (2007): S515-7. doi: https://doi.org/10.1111/j.1872-034X.2007.00232.x
Iwasaki S, Akisawa N, Saibara T, Onishi S. Fibrate for treatment of primary biliary cirrhosis. Hepatol Res. 2007 Oct;37:S515-7. doi: 10.1111/j.1872-034X.2007.00232.x. PMID: 17931214.
Copy Download .nbib Format: NLM
Share it on

Hepatol Res. 2007 Oct;37:S515-7. doi: 10.1111/j.1872-034X.2007.00232.x.

Fibrate for treatment of primary biliary cirrhosis.

Hepatology research : the official journal of the Japan Society of Hepatology

Shinji Iwasaki, Naoaki Akisawa, Toshiji Saibara, Saburo Onishi

Affiliations

  1. Department of Gastroenterology and Hepatology, Kochi Medical School, Nankoku, Kochi, Japan.

PMID: 17931214 DOI: 10.1111/j.1872-034X.2007.00232.x

Abstract

Recent studies of the effectiveness of ursodeoxycholic acid (UDCA) therapy in patients with primary biliary cirrhosis (PBC) reported that UDCA therapy did not necessarily stop the progression of liver fibrosis in all patients, even those with early stage PBC. Thus, there is a need for more effective treatments that could prevent asymptomatic PBC from progressing to the icteric stage. Bezafibrate is effective in approximately two-thirds of non-icteric patients who have not shown a complete response to UDCA. Serum bilirubin, aspartate aminotransferase and gamma-guanosine 5'-triphosphate levelswere significantly lower in patients who responded to additional bezafibrate on univariate analysis. The putative mechanism by which bezafibrate acts in cholestasis is by increasing phospholipid output into bile, which forms micelles with the hydrophobic bile acid that reduces its toxicity.

Publication Types